Alliance Pharma plc (DVL.F)
- Previous Close
0.3880 - Open
0.3720 - Bid --
- Ask --
- Day's Range
0.3720 - 0.3900 - 52 Week Range
0.3560 - 0.8200 - Volume
30 - Avg. Volume
0 - Market Cap (intraday)
220.75M - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 22, 2023
- 1y Target Est
--
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics. It provides its products under the Aloclair, Anbesol, Asthon and Parsons, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. Alliance Pharma plc was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.
www.alliancepharmaceuticals.com285
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DVL.F
Performance Overview: DVL.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DVL.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DVL.F
Valuation Measures
Market Cap
219.62M
Enterprise Value
334.10M
Trailing P/E
--
Forward P/E
7.48
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.06
Price/Book (mrq)
0.65
Enterprise Value/Revenue
1.96
Enterprise Value/EBITDA
26.71
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.15%
Return on Assets (ttm)
2.99%
Return on Equity (ttm)
-2.46%
Revenue (ttm)
170.05M
Net Income Avi to Common (ttm)
-7.06M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
26.11M
Total Debt/Equity (mrq)
45.00%
Levered Free Cash Flow (ttm)
19.15M
Company Insights: DVL.F
DVL.F does not have Company Insights